Jan 7, 2020 | CMT Research Updates, Research news, Small Molecule Therapies, Therapy Types
Can axon degeneration be prevented in CMT? By Dr. Grace Pavlath, PhD I’m often asked if a therapy for one type of CMT could be beneficial in another. There are over 100 different genes known to cause CMT; they either directly disrupt myelin or axon integrity of...
Sep 18, 2019 | CMT Research Updates, Press Releases, Research news, Small Molecule Therapies, Uncategorized
Just nine months ago, we announced a milestone-based, research collaboration with AcuraStem to test thousands of compounds aimed at producing effective treatments for CMT2A. We are very pleased to report that AcuraStem has completed phase one of the CMT2A project and...
Aug 2, 2019 | CMT Research Updates, Press Releases, Research news, Small Molecule Therapies
Paving pathways for mission critical projects CMT Research Foundation is partnering with Dr. Maurizio D’Antonio of I.R.C.C.S. Ospedale San Raffaele, in Milan, Italy to fund the lab’s research of Myelin Protein Zero (MPZ), the gene associated with CMT1B. Dr....
Feb 11, 2019 | CMT Research Updates, Research news, Small Molecule Therapies
The FDA Grants Fast Track Designation to Pharnext’s PXT3003 for CMT1A Pharnext, an advanced clinical-stage biopharmaceutical company, created a drug combination of three drugs: baclofen, naltrexone and sorbitol known as PXT3003. Baclofen is known to relieve...
Dec 20, 2018 | Press Releases, Research news, Small Molecule Therapies, Uncategorized
Focus will be on expansion of AcuraStem’s patient-based discovery platform, iNeuroRx™, to leverage patient neurons and advanced informatics technology to identify promising drugs ATLANTA (December 20, 2018)The newly launched CMT Research Foundation (CMTRF), a...
Important Research News Announcements